Aggregator
心理或教育干预(或两种结合)能否减少居家老年人跌倒的发生?
无创正压通气治疗儿童急性哮喘
Water fluoridation less effective now than in past
An updated Cochrane review has found that the dental health benefits of adding fluoride to drinking water may be smaller now than before fluoride toothpaste was widely available.
The team of researchers from the Universities of Manchester, Dundee and Aberdeen reviewed the evidence from 157 studies which compared communities that had fluoride added to their water supplies with communities that had no additional fluoride in their water. They found that the benefit of fluoridation has declined since the 1970s, when fluoride toothpaste became more widely available.
The contemporary studies were conducted in high-income countries. The impact of community water fluoridation in low- and middle-income countries is less clear, due to the absence of recent research.
Fluoride, used in many commercially available toothpastes and varnishes, is known to reduce tooth decay. Governments in many countries have added fluoride to the drinking water supply to improve population oral health, although there are polarized views on whether this is the right action to take.
“When interpreting the evidence, it is important to think about the wider context and how society and health have changed over time,” says co-author Anne-Marie Glenny, Professor of Health Sciences Research at the University of Manchester. “Most of the studies on water fluoridation are over 50 years old, before the availability of fluoride toothpaste. Contemporary studies give us a more relevant picture of what the benefits are now.”
Results from studies conducted after 1975 suggest that the initiation of water fluoridation schemes may lead to slightly less tooth decay in children’s baby teeth. Analysis of these studies, covering a total of 2,908 children in the UK and Australia, estimates that fluoridation may lead to an average of 0.24 fewer decayed baby teeth per child. However, the estimate of effect comes with uncertainty, meaning it’s possible that the more recent schemes have no benefit. By comparison, an analysis of studies with 5,708 children conducted in 1975 or earlier estimated that fluoridation reduced the number of decayed baby teeth, on average by 2.1 per child.
The same contemporary studies (conducted after 1975) also looked at the number of children with no decay in their baby teeth. The analysis found that fluoridation may increase the number of children with no tooth decay by 3 percentage points, again with the possibility of no benefit.
The review was only able to draw conclusions about the impact on children’s teeth, with similar findings across both baby and permanent teeth. There were no studies with adults that met the review’s criteria.
“The evidence suggests that water fluoridation may slightly reduce tooth decay in children,” says co-author Dr Lucy O’Malley, Senior Lecturer in Health Services Research at the University of Manchester. “Given that the benefit has reduced over time, before introducing a new fluoridation scheme, careful thought needs to be given to costs, acceptability, feasibility and ongoing monitoring.”
Advocates have suggested that one of the key benefits of water fluoridation is that it reduces oral health inequalities. This updated review sought to examine this question and did not find enough evidence to support this claim, although this doesn’t necessarily mean there is no effect.
The review’s findings accord with recent observational studies including the LOTUS study, which compared anonymised dental health records with water fluoridation status for 6.4 million adults and adolescents in England between 2010 and 2020. People in fluoridated areas needed slightly fewer invasive dental treatments with no significant impact on inequalities.
“Contemporary evidence using different research methodologies suggest that the benefits of fluoridating water have declined in recent decades,” says Tanya Walsh, Professor of Healthcare Evaluation at the University of Manchester, co-author on both the Cochrane review and the LOTUS study. “Oral health inequalities are an urgent public health issue that demands action. Water fluoridation is only one option and not necessarily the most appropriate for all populations.”
“Whilst water fluoridation can lead to small improvements in oral health, it does not address the underlying issues such as high sugar consumption and inadequate oral health behaviours,” says co-author Janet Clarkson, Professor of Clinical Effectiveness, University of Dundee. “It is likely that any oral health preventive programme needs to take a multi-faceted, multi-agency approach.”
Iheozor-Ejiofor Z, Walsh T, Lewis SR, Riley P, Boyers D, Clarkson JE, Worthington HV, Glenny A-M, O'Malley L. Water fluoridation for the prevention of dental caries. Cochrane Database of Systematic Reviews TBD, Issue TBD. Art. No.: CD010856. DOI: 10.1002/14651858.CD010856.pub3.
Friday, October 4, 2024
Drugs to prevent malaria in HIV-positive pregnant women
预防艾滋病毒阳性孕妇感染疟疾的药物
体感游戏对痴呆或轻度认知障碍患者的益处与风险?
Cochrane welcomes global commitment to evidence synthesis
At the United Nations Summit of the Future, two major funding bodies announced £54.2 million of new funding for evidence synthesis: £45 million from Wellcome and £9.2 million from UK Research and Innovation (UKRI).
The announcements represent significant investment in evidence synthesis to help tackle global inequity and address the UN’s Sustainable Development Goals. Cochrane was represented at the summit by our Editor in Chief, Dr Karla Soares-Weiser.
“It is invigorating to see major global funders recognizing the importance of evidence synthesis in addressing the challenges facing the world today and in the future,” says Karla. “This significant investment has the potential to catalyze a step change in evidence synthesis, making it more timely, relevant and equitable. Cochrane has a proud history of advancing evidence synthesis, and we stand ready to support this vital global effort. I am especially excited at the potential to reduce global inequities in both producing and accessing high-quality evidence.”
Both funding calls are aimed at building infrastructure to support rapid evidence synthesis projects so that policymakers have access to the latest evidence on a given topic. The Wellcome announcement focuses on ‘living evidence synthesis’, where systematic reviews are continually updated so they always reflect the latest evidence. Wellcome’s announcement notes that ‘the Cochrane Collaboration, which produces gold-standard evidence syntheses in medicine, increasingly backs living evidence models’.
Living evidenceCochrane is a pioneer of living systematic reviews, having published the world’s first living systematic reviews in 2017. Lessons from the pilot project were published in 2019, in a project co-led by Professor Tari Turner at Cochrane Australia, who serves on Cochrane’s Editorial Board and is Academic Director of the Australian Living Evidence Collaboration.
“It’s fantastic to see this global commitment to living evidence and recognition of Cochrane's leadership in this area,” says Tari. “The new funding is fantastic news for both evidence synthesis professionals and decision-makers who need up-to-date evidence. Living reviews come with many opportunities and challenges which we identified in our pilot programmes, and it’s great to see them getting the attention they deserve.”
Tuesday, September 24, 2024
Which approaches help with recovery after a broken ankle in adults?
Cochrane’s pioneering role in living evidence
As the pace of new research accelerates, keeping systematic reviews up-to-date with the latest evidence has become increasingly vital. Cochrane is at the forefront of this evolution with our leadership in living systematic reviews (LSRs)—a dynamic approach that ensures evidence remains current and relevant.
What's a systematic review?
A systematic review attempts to identify, appraise, and synthesize all the empirical evidence that meets pre-specified eligibility criteria to answer a specific research question. Researchers conducting systematic reviews use explicit, systematic methods that are selected with a view aimed at minimizing bias, to produce more reliable findings to inform decision making.
For those new to the concept, here's a short video from Cochrane Consumers and Communication that explains what a systematic review is, how researchers prepare them, and why they’re a crucial part of making informed health decisions - both for professionals and the public.
What is living evidence?
Living evidence refers to a systematic review that is continually updated to incorporate new and relevant information as it becomes available. Unlike traditional systematic reviews, which may be updated infrequently or not at all, living systematic reviews (LSRs) are underpinned by ongoing, active monitoring of the evidence base.
Key Features of LSRs:
- Continual Monitoring: LSRs involve regular, often monthly, searches for new evidence.
- Immediate Updates: New important evidence, including data, studies, or information, is promptly included.
- Up-to-Date Communication: The status of the review and any new evidence are communicated clearly and regularly.
While LSRs employ the same core review methods as other Cochrane Reviews, they also incorporate predefined and transparent decisions on how frequently new evidence is sought, how it is integrated, and the rationale behind these decisions. Cochrane continues to innovate by providing updated information on the status of our reviews and each updated review is assigned a new citation and DOI, linking it to previous versions and ensuring the most current evidence is available.
Watch all the videos from this series
Why living systematic reviews?
LSRs represent a significant advancement in evidence synthesis, connecting evidence and practice more seamlessly than traditional methods. They are hugely valuable to healthcare professionals, decision-makers, guideline developers, policy-makers, funders, consumers (patients and carers), and publishers who require up-to-date evidence for informed decision-making.
Technological advancements, such as online platforms, linked data, and machine learning, have made large-scale living evidence approaches feasible. The growth of collaborative research, open data initiatives, and citizen science also supports the maintenance of high-value datasets and LSRs - areas that Cochrane is also leading.
Cochrane’s role and innovations
Since launching the world's first pilot living reviews in 2017, Cochrane has been a trailblazer in this field. Professor Tari Turner, member of the Cochrane Library Editorial Board and Director of the Australian Living Evidence Collaboration based at Cochrane Australia, has been instrumental in developing and applying living evidence approaches. According to Tari:
"Living evidence synthesis is transforming how we navigate uncertainty and make evidence accessible. By continually updating our living reviews, Cochrane is ensuring that decision-makers have the most current information at their fingertips."
Living systematic reviews are a testament to Cochrane's commitment to producing evidence that is not only trustworthy but also continuously relevant. As we move forward, we remain dedicated to leading in this space and advancing the field of evidence synthesis.
Monday, October 28, 2024辅助技术能否帮助改善成人中风后因肌肉和肌腱缩短而导致的关节僵硬?
对于尚未扩散至身体其他部位的低风险妊娠滋养细胞肿瘤,“保留生育能力”手术有哪些益处和危害?
治疗贫血的药物是否有助于预防急性肾损伤?
Psychedelic-assisted therapy for treating anxiety, depression and existential distress in people with life-threatening diseases
Does vitamin D supplementation benefit, harm, or have no effects on pregnant women or their babies?
Cochrane seeks Managing Editor Remote/Flexible
Title: Managing Editor
Specifications: 12 months Fixed Term – Contract
Salary: £42,000 per annum
Location: UK, Germany or Denmark – Remote/Flexible
Closing date: 30 September 2024
Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.
Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into five directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.
Reporting to the Senior Managing Editor and working with members of the Editorial Production and Methods Directorate, the role holder will need to have good awareness of Cochrane guidance for different types of standard and complex systematic reviews (intervention, qualitative, diagnostic test accuracy, prognosis, rapid and overview), plan how they will need to be handled in their team, and work to ensure that deadlines are met. The role holder will also be required to ensure that pilots aimed at innovating the editorial process can be supported as needed.
Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.
Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.
You can expect:
- An opportunity to truly impact health globally
- A flexible work environment
- A comprehensive onboarding experiences
- An environment where people feel welcome, heard, and included, regardless of their differences
Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.
How to apply
- For further information on the role and how to apply, please click here.
- The deadline to receive your application is 30 September 2024.
- The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
- Read our Recruitment Privacy Statement
Cochrane announces the 2026 Colloquium in India
Cochrane is excited to announce that its flagship event, the Cochrane Colloquium, will be hosted in India in October 2026. Building on the momentum of previous successful gatherings, including the Cochrane London Colloquium and the Global Evidence Summit in Prague, this eagerly awaited event will unite the global healthcare evidence synthesis community to foster collaboration, share insights, and drive lasting impact.
The Cochrane Colloquium is an annual international conference that brings together a diverse range of participants, including researchers, healthcare professionals, policymakers, patients, and carers. It provides a unique platform for those passionate about evidence synthesis and evidence-based healthcare to share knowledge, engage in practical workshops, and explore innovative approaches. The event is also a vibrant space for networking, making it a crucial part of the global effort to improve health outcomes through reliable, high-quality evidence.
The 2026 Colloquium will focus on themes that resonate across healthcare and policy sectors: Bridging Gaps, Global Evidence, Local Impact, and Equitable Action. These themes will drive discussions on the importance of evidence in addressing health disparities and achieving equitable healthcare solutions around the world.
Catherine Spencer, CEO of Cochrane, shared her enthusiasm: “The 2026 Cochrane Colloquium will be pivotal for anyone involved in evidence-based healthcare. These themes are crucial for advancing evidence production, implementation, and policy, and we are excited to develop a programme that addresses these vital areas.”
The Cochrane India Network were at the recent Global Evidence Summit. At their stand they engaged with attendees and provided information about the 2026 Cochrane Colloquium, receiving an enthusiastic response. During the closing plenary, they showcased a video and extended a heartfelt invitation to join them in India for the upcoming Colloquium.
Dr Neeta Mohanty from Cochrane India expressed excitement about hosting the Colloquium."It is an honour to invite you all to India for the 2026 Colloquium. Attending previous Colloquia has been a highlight for our team and we are looking forward to welcoming you and being your warm hosts."
We are excited to put together an engaging programme and to bring the community together. Stay tuned for more updates and sign up for the 2026 Colloquium newsletter to keep in touch and be among the first to receive news and announcements.
Wednesday, September 25, 2024